Sunday, May 17, 2009

New Education Series "Making Methadone Safe"

A new Education Series (Number 11) Making Methadone Safe has been developed to help patients -- both addiction treatment patients and pain patients -- keep their methadone safe.

Increase in Methadone Related Deaths by 390%

Methadone related deaths have increased dramatically, from 1999 through 2004 there was a 390 percent increase. Other deaths attributed to opioids have also increased but only by 90 percent, however they constitute a much larger percentage of the total for opioid-related deaths. A SAMHSA report found that the majority of methadone-related deaths involve abuses that were prescribed for pain management. Methadone deaths attributed to Opiate Treatment Programs (OTPs) have not increased.

Unfortunately it is the OTP deaths that make the news and methadone programs have particularily become targets because they are easy to blame.

It is important that all persons taking methadone keep there medication safe and this Education Series was developed to provide resources and ways to keep methadone safe.

You can download the new Education Series at our website.

Sunday, April 26, 2009

New Name: National Alliance for Medication Assisted Recovery

National Alliance of Methadone Advocates
Press Release


Contact Person: Joycelyn Woods, Executive Director
edirector@methadone.org
1.212.595.6262

FOR IMMEDIATE RELEASE
APRIL 26, 2009



New Name: National Alliance for Medication Assisted Recovery


It is especially fitting at this AATOD conference in New York that the Board of Directors of the National Alliance of Methadone Advocates, the premier patient advocacy organization in the opiate addiction recovery community, established in 1988 in this very city, announces an important change to its identity. It will now be doing business as the National Alliance for Medication Assisted Recovery, or NAMA Recovery. NAMA Recovery has 25 chapters across the United States and 15 international affiliate chapters from England to Denmark and India to Australia, providing information, education and advocacy support to patients in medication assisted addiction treatment utilizing methadone and buprenorphine.

NAMA Recovery is the umbrella organization for the M.A.R.S. Project, a CSAT (Center for Substance Abuse Treatment) funded Recovery Support Services Grant grantee. M.A.R.S. (Medication Assisted Recovery Services) is a peer recovery project based on the belief that when methadone patients receive training about addiction, its treatment and recovery they will feel better about themselves and do better in treatment and life. It is providing patients of medication assisted treatment education about the science of addiction, information on nutrition and health, peer mentoring, women- and Hispanic-specific recovery services, even a M.A.R.S. book club, all in a location near the treatment clinic where the patient can be mentored and grow. M.A.R.S. is the first truly “peer to peer” recovery endeavor in opiate addiction treatment in the United States with MAT patients educating and mentoring MAT patients with significant accomplishments and successes.

The Executive Director of NAMA Recovery is Joycelyn Woods and the Director of the M.A.R.S. Project is Walter Ginter.

Monday, February 23, 2009

Rokki's NewTube Message

See our President Rokki Baker's NewTube message about Drug Policy.

The message was taped at the IDUD 2008 Meetings hosted by NAMA’s Danish Affiliate, BrugerForeningen (BF).

Check out Rokki's Talk at YouTube.

Monday, February 09, 2009

Editorial Comment: AATODs Letter to Treatment Magazine

January 9, 2009


Ted Jackson Editor and Publisher
Treatment Magazine
Post Office Box 3 196
Lantana, Florida 33465

Dear Mr. Jackson:

I am writing with regard to the "Publisher's Note," "Another Use for Methadone?!!," which was published in the November 2, 2008 edition of Treatment Magazine.

You note that methadone is "...one of the most studied drugs on earth. "It would be helpful for you to read some of the literature because you would find that there is absolutely no scientific evidence that supports the statement that methadone " ...rots your teeth." It is useful to cite a statement from the National Institutes of Health Consensus Statement of November 1997.

"Many of the barriers to effective use of methadone maintenance Treatment in the treatment of opioid dependence stem from misperceptions and stigmas attached to opioid dependence the people who are addicted those who treat them and the settings in which services are provided."

An impartial observer might conclude that your "Publisher's Note" further stigmatized this long-proven and effective treatment for opioid addiction. The Association welcomes the expansion of buprenorphine medication and an increasing number of opioid treatment programs are using buprenorphine products in addition to methadone to treat chronic opioid addiction. With regard to methadone being antiquated, you should know that there is a major expansion in the use of this medication to treat chronic opioid addiction in Europe, China and Vietnam with an interest to use this medication in other developing nations.

You also indicate that "...the principal use for methadone is as a maintenance replacement for other opiates." This has been the case for the past four decades to present, there are approximately 260,000 patients being treated with methadone in 1,203 registered and certified OTPs. There are more than 700,000 patients who receive prescriptions for methadone from private physicians in treating chronic pain.

After years of struggling to support rigorous scientific evaluations of medications and to promote evidence-based treatment for opioid addiction, it is extremely disheartening to have the publisher of a treatment magazine for the addiction industry make such unfounded comments.

Sincerely yours,


Mark W. Parrino, MPA
President

Tuesday, November 18, 2008

IDUD 2008 Gathers Top International Advocates

National Alliance of Methadone Advocates
Press Release




Contact Persons:
Joycelyn Woods, Executive Director, edirector@methadone.org
Roxanne Baker, President, president@methadone.org
Phone/Fax: 212-595-NAMA




For Release:
November 17, 2008



BrugerForeningen (BF), NAMA’s Danish Affiliate hosted the International Drug Users’ Day (IDUD) in Copenhagen Denmark October 30 to November 3, 2008 to bring together the top user activists from around the world.




IDUD event was founded in 1995 by the national Dutch umbrella user organisation Landelijk Steunpunt Druggebruikers (LSD) and their director Theo van Dam. IDUD was an international conference and celebration for drug user activists to network, share ideas and unite user organizations. The last IDUD was hosted by BF in 2003 and gathered 96 activists from 16 different nations. The event was documented by Howard Lotsof (NAMA and Dora Weiner Foundation) and can be read on the BF website at http://www.brugerforeningen.dk/bfny.nsf/engelsk/nl003?OpenDocument&S=UK




Ths year’s event brought together 120 activists from around the world. Presentations included:





  • Méta d’âme’s new facility and the peer delivered services.

  • Syringe and needle distribution in jails and how to go about it.

  • Lifesaving prevention of peer distributed Naloxone to reduce overdose deaths.

  • Making user unions accepted in wider society by providing services (i.e. syringe patrols & prevention lectures at schools) and using the parents and relatives of drug users to promote the union.

  • Improving the lives of drug users through the union’s advisory services to the community and advocacy.

  • Publications: user magazines and special concepts such as the J-Key Cards to educate drug users and promote user organizations.

  • Heroin trials and treatment.

  • Memorial Day events for deceased drug users – 21 July.

  • Human rights for drug users and what user organizations should know.

  • Attracting funding for user groups and interest organizations.

  • Working with journalists and using the media to promote user organizations.



This was the fifteenth year anniversay of BrugerForeningen and on November 1, 2008 120 activists were served a three course meal. After dinner the gala party continued with a live band consisting of activists musicians from Italy, Australia, Denmark, Norway and Belgium with Pat O’Hare in lead.






NAMA presented Joergen Kjaer and BF the International Advocate of the Year Award for 2009 for “...the exceptional work they have done in Denmark and throughout the world advocating for drug users and those who are voiceless. Their efforts have resulted in a more united network of user organizations throughout the world, helped to create a unified voice and brought the issues that confront drug users to the public.”




Congratulations to BF and Happy Anniversary with many more successful years to come.




Photos of the events can be seen at these links.


IDUD Conference:


http://cid-19d32a68e122a231.spaces.live.com/photos/cns!19D32A68E122A231!110/


Gala Dinner:


http://cid-19d32a68e122a231.spaces.live.com/photos/cns!19D32A68E122A231!425/

Saturday, November 15, 2008

Variations In Key Genes Increase Caucasians’ Risk Of Heroin Addiction

ScienceDaily (Oct. 5, 2008)

Sometimes, small changes do add up. In the case of addictive diseases, tiny variations in a few genes can increase or decrease the likelihood of some people developing a dependency on heroin. Now, by examining a select group of genetic variants in more than 400 former severe heroin addicts, Rockefeller University researchers have identified several genetic variations in American and Israeli Caucasians that influence the risk for becoming addicted to one of the world’s most powerful substances.

--------------------------------------------------------------------------------
In a collaborative effort with statistical geneticists and several methadone clinics, scientists led by Mary Jeanne Kreek, head of the Laboratory of the Biology of Addictive Diseases, analyzed 1,350 variations in 130 genes and found nine, from six genes, that were either more or less common in recovering heroin addicts when compared to Caucasians with no history of drug abuse. These small changes in the gene sequences can cause significant changes in protein function that can influence addictive behavior — changes that may affect people of different ethnic background differently.

“The idea of ‘personalized medicine’ makes this field really exciting but also very complicated,” says Orna Levran, a senior research associate in the Kreek laboratory and first author of the study. “Although seven of these variants increase the risk for developing heroin addiction in Caucasians, the same seven may not have the same effect in other populations. So ethnicity and, more precisely, genetic information in each individual may become important factors for treating and diagnosing addictions to different drugs.”

In their analysis, Kreek, Levran and their colleagues looked at a string of letters called nucleotides, the building blocks that make up genes. In each of the six genes, at least one letter is replaced by another, a genetic variation known as a single nucleotide polymorphism, or SNP. The researchers found that all of the single-letter variations exist in parts of the genes that do not translate into proteins but instead may have a regulatory or a structural effect.

Out of the nine SNPs, the group found six in the μ, δ and κ opioid receptors, a finding that reinforces the idea, and many other findings of the Kreek laboratory, that opiate receptors play a major role in severe heroin addiction. The remaining three SNPs were found in genes coding for the serotonin receptor 3B, casein kinase 1 epsilon, which acts as a regulator of the circadian clock genes, and galanin, which modulates appetite and alcohol consumption. This is the first study to show that specific variants in these genes are associated with heroin addiction, explains Levran.

The SNPs in the κ opioid receptor and casein kinase 1 genes were found more in the control group than the heroin addicts’ group, suggesting that they conferred protection from heroin addiction — not vulnerability to develop addiction.

“Individually, these SNPs probably have a small effect,” explains Levran, “but collectively, we are seeing that they could have a larger effect. One of the goals now is to find all of these gene variants and assess how they influence people of different ethnic backgound.”

--------------------------------------------------------------------------------

Journal reference:

Levran, Londono, O'Hara, Nielsen, Peles, Rotrosen, Casadonte, Linzy, Randesi, Ott, Adelson, Kreek. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain

and Behavior, 2008; 7 (7): 720

Adapted from materials provided by Rockefeller University.

ABSTRACT

Genetic susceptibility to heroin addiction: a candidate gene association study

O. Levran*,†, D. Londono ‡ , K. O'Hara † , D. A. Nielsen † , E. Peles § , J. Rotrosen ¶ , P. Casadonte ¶ , S. Linzy**, M. Randesi † , J. Ott ‡,†† , M. Adelson †,§,** M. J. Kreek †
  † The Laboratory of the Biology of Addictive Diseases, and  ‡The Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, USA,  §Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Elias Sourasky Medical Center, Tel Aviv, Israel,  ¶VA New York Harbor Healthcare System and NYU School of Medicine New York, NY and  **Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse, Treatment and Research, Las Vegas, NV, USA, and  ††Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

Correspondence to   *O. Levran, The Laboratory of the Biology of Addictive Diseases, 1230 York Avenue, Box 171, The Rockefeller University, New York, NY 10065, USA. E-mail: levrano@rockefeller.edu

Copyright Journal compilation © 2008 Blackwell Publishing Ltd/International Behavioural and Neural Genetic Society

KEYWORDS: Association study, candidate gene, heroin addiction

Heroin addiction is a chronic complex disease with a substantial genetic contribution. This study was designed to identify genetic variants that are associated with susceptibility to develop heroin addiction by analyzing 1350 variants in 130 candidate genes. All subjects had Caucasian ancestry. The sample consisted of 412 former severe heroin addicts in methadone treatment, and 184 healthy controls with no history of drug abuse. Nine variants, in six genes, showed the lowest nominal P values in the association tests (P < 0.01). These variants were in noncoding regions of the genes encoding the mu (OPRM1; rs510769 and rs3778151), kappa (OPRK1; rs6473797) and delta (OPRD1; rs2236861, rs2236857 and rs3766951) opioid receptors; the neuropeptide galanin (GAL; rs694066); the serotonin receptor subtype 3B (HTR3B; rs3758987) and the casein kinase 1 isoform epsilon (CSNK1E; rs1534891). Several haplotypes and multilocus genotype patterns showed nominally significant associations (e.g. OPRM1; P = 0.0006 and CSNK1E; P = 0.0007). Analysis of a combined effect of OPRM1 and OPRD1 showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). None of these associations remained significant after adjustment for multiple testing. This study suggests the involvement of several genes and variants in heroin addiction, which is worthy of future study.

--------------------------------------------------------------------------------

Sunday, October 05, 2008

Notice: Medicaid Medicare New Rule Put on Hold

October 3, 2008

NAMA has been working behind the scenes with provider organizations regarding a New Rule proposed by the Center for Medicaid and Medicare that would set low limits for both Medicaid and Medicare. But the greatest impact it would have had would be to stop all Medicaid funding for methadone treatment.

It was worded in a way that if Medicare did not cover a service then Medicaid would also have to eliminate that service. It not only impacted methadone treatment but many other services that are not provided within a hosptial, such as: dialysis, women's services, HIV services, disabled children and mental health. Since the majority of programs are not hospital based and Medicaid funding would be ended.

The Center for Medicaid and Medicare also proposed 6 other rules that have also been put on hold until April 2009.

Here are some documents you can read about the rule.

Upper Payment Limit Federal Register
CMS PROPOSED RULE Revised
CMS Upper Payment Limit Rule-Coalition Response
Comment on Outpatient Hospital

Victory for Addiction Equity: Wellstone-Domenici Bill Passed by Congress and Signed by President Today

After twelve years frustrating hard work determined advocacy has finally produced the victory. Today Congress passed the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 - comprehensive mental health and addiction parity legislation in honor of the late Senator Paul Wellstone. The bill was included in financial bailout package passed by the Senate on Monday and the House today. It now moves to the President's desk.

The parity bill does not require health-insurance plans to cover addiction or mental health, but insurers will now be barred from imposing any caps or limits on behavioral healthcare service that are not applied to other health conditions. Most insurance plans do include behavioral-healthcare coverage, and advocates say that past experience shows that passage of state-level parity laws has not led to insurers dropping such coverage.

We are still only half way there but that is better than not being there at all.  The bill will start to pave the way so that all Americans can receive help for their addiction.

NAMA salutes Faces & Voices for their strong support of this bill and medication assisted treatment.

Sunday, September 07, 2008

Gulf Coast Area: Did Emergency Preparations Work?

National Alliance of Methadone Advocates
Press Release

Contact Person:
Joycelyn Woods, Executive Director
edirector@methadone.org
1.212.595.6262

For Release 
September 6, 2008

 

Did Gulf Coast Programs Give Patients Enough Preparations for Gustav?

Policy Makers and Regulators are all congratulating one another for the great work done during Gustav. Patients got out of town and were given enough medication until they could get back. Thus far no complaints.  However all seemed to go well because Gustav ended up a Category 2 hurricane but what if it had been a Category 4 or greater.

NAMA needs to know if patients in the Gulf Coast Area had the correct emergency information to get through a larger hurricane. Can you answer some questions?

* * *

When did your program notify you to come in and get emergency evacuation medication?

If your area was not evacuated then did your program give you information what to do in case evacuation occurred?

Whether you evacuated or not how many days medication were you given and on what day?

Were you told what to do in case you could not return within the amount of days medication you were given?

Were you given information of what to do in case you could not reach your program after the hurricane?

Program Name:

City:

State:

 

Send your answers to edirector@methadone.org

We will take your answers and notify the proper authorities about what happened right and what did not happen that should have.

 

 

Saturday, August 30, 2008

Hurricane Gustav Threatens Texas to Mobile, Including New Orleans

 

National Alliance of Methadone Advocates
Press Release

Contact Person:
Joycelyn Woods, Executive Director
edirector@methadone.org
1.212.595.6262

For Release
August 31, 2008

 

While most Americans are enjoying the Labor Day Weekend residents from Galveston. TX to Mobile, Alabama are being warned about Hurricane Gustav. In the middle of the estimated path is New Orleans.

 

NAMA has already begun to get phone calls from patients in the area who are being told to evacuate.  One patient was just given 4 days medication and no other instructions in the case they could not return.  Neither were they provided with a letter stating their dose and other information.

Advise to Patients

If you need to evacuate get a letter from your clinic.  The standard Travel Letter that is given to patients should be enough that states you are patient, that you need to take ____ mgs of methadone a day and information about contacting the clinic.

Get a list of programs in the area in case you can not get back to your program and the State Methadone Authority.

 

New Orleans Programs

DRD New Orleans Medical Clinic
417 South Johnson Street
New Orleans, LA 70112 (504) 524-4701

Desire Narcotic Rehabilitation Ctr Inc
4116 Old Gentilly Road
New Orleans, LA 70126 (504) 301-8871

New Orleans Narcotic Treatment Center
7606 Westbank Expressway
Marrero, LA 70072 (504) 347-1120

Choices of Louisiana Inc
128 Woodland Drive
La Place, LA 70068 (985) 651-3777

Baton Rouge Treatment Center Inc
11445 Reiger Road
Baton Rouge, LA 70809 (225) 932-9867

If you need a program farther than New Orleans or you are in another state you can use the Treatment Facility Locator at:

 http://findtreatment.samhsa.gov/

State Methadone Authorities

Brenda  Lands
Louisiana Office for Addictive Disorders 
1201 Capital Access Road, 4th Floor 
Baton Rouge, LA 70802
Telephone: (225) 342-8735 
Fax: (225) 342-3931 

Christine  Ramirez
1100 West 49th Street 
Austin, TX 78756-3199
Telephone: (512) 834-6700 x2146 
Fax: (512) 834-6638 

Robert  Wynn
Department of Mental Health
P.O. Box 301410, 100 North Union Street
Montgomery, AL 36130-1410
Telephone: (334) 242-3956
Fax: (334) 242-0759

 

NAMA will continue to post information as it becomes available.

Finally NAMA Website Goes Back Up

 

National Alliance of Methadone Advocates
Press Release

Contact Person:
Joycelyn Woods, Executive Director
edirector@methadone.org
1.212.595.6262

For Release
August 31, 2008

 

It has been nearly 6 months since Calyx the service that has hosted the NAMA website went down. Several attempts to get the server up and running again have been attempted and failed. This left NAMA with the problem of having to find a service that could host a site the size and activity of the website but that would not be expensive.  We think we have found it and so the website is slowing going back up.

It will take us several weeks to get the website up and equal to what it was when it went down.  Many pages need updating while others may have broken links, missing pages, lost images and vanished pictures but we will track them down and upload them if you tell us what is missing.

Tell Us When You Find An Error

If you find something missing on a page send us a message with:

the name of the page,

the link and

what is missing,

to: whoops@methadone.org

Kerry Wolf New We Speak Methadone Administrator

National Alliance of Methadone Advocates
Press Release

Contact Person:
Joycelyn Woods, Executive Director
edirector@methadone.org
1.212.595.6262

For Release
August 6, 2008

NAMA is pleased to announce that Kerry Wolf will be the new We Speak Methadone (WSM) Administrator. Ms. Wolf has been the second in command at WSM for several years and is already known at the forum for her commitment to spreading the truth and telling the untold success stories about methadone. Her energies sometimes seem to be endless and we at NAMA are very fortunate to have her.

Charles "Hoss" Kitts has been the administrator of WSM for many years.  He will most undoubtedly be missed for his caring and concern for patients that need help.  However Hoss is not actually leaving the family of NAMA as he will still be Director of the West Virginia chapter and we hope to see him posting at WSM on occasion.

Monday, August 04, 2008

Methadone Promising in Hard-To-Treat Leukemia

By Karla Gale
Reuters, August 1, 2008


NEW YORK (Reuters Health) - Methadone, a drug used to treat people addicted to heroin and other opioid drugs, holds promise as a new treatment for leukemia, especially treatment-resistant leukemia, according to results of a study.

Laboratory tests show that methadone kills leukemia cells without harming healthy blood cells, researchers at the University of Ulm in Germany report in a paper published today in the journal Cancer Research. Methadone was even effective in killing leukemia cells resistant to killing by chemotherapy and radiation.

"Leukemia cells express opioid receptors, to which methadone binds," study chief Dr. Claudia Friesen told Reuters Health. "Surprisingly, we found that methadone kills leukemia cells efficiently. We never expected that."

These results "provide the foundation for new strategies using methadone as an additional anticancer drug in leukemia therapy, especially when conventional therapies are less effective," the investigators conclude.

"We find this very exciting, because once conventional treatments fail, which occurs in old and also in young patients, they have no other options," Friesen said.

She predicts that methadone will have similar effects in other cancers that express opioid receptors. "In our lab we found that we also can kill solid tumors," she added.

Friesen and her team are studying methadone alone and in combination with other chemotherapy drugs in animal models of cancer.

SOURCE: Cancer Research, August 1, 2008.

Other Links

Methadone Breaks Resistance In Untreatable Forms Of Leukemia
Science Daily, August 4, 2008

Methadone Kills Resistant Leukemia Cells
HealthDay News, August 1, 2008

Lab Study Shows Methadone Breaks Resistance in Untreatable Forms of Leukemia
American Association for Cancer Research, August 1, 2008

Posted: August 4, 2008

Friday, February 15, 2008

Indiana Poses New Regulations That Would Force Hundreds Out of Treatment

National Alliance of Methadone Advocates
Press Release

Contact Persons: Roxanne Baker, President
president@methadone.org
Joycelyn Woods, Executive Director
edirector@methadone.org
1.212.595.nama

For Release
February 15, 2008


Indiana Poses New Regulations
That Would Force Hundreds Out of Treatment


The Indiana Legislature is proposing some excessive regulations that will force hundreds of patients out of treatment. And those seeking treatment will find barriers that make it nearly impossible to access treatment.

The Indiana House Bill 1258 calls for:


  1. Excessive and unnecessary urine testing,

  2. Discharge any patient testing positive for any drug not in their treatment plan,

  3. Not allow anyone under 18 years in a program unless they are being treated there or transporting a patient,

  4. Requires a designated driver for any patient leaving the program.



These regulations will force programs to discharge patients that test positive for any drug that is not part of their treatment plan. This means that any patient that develops a secondary addiction while in treatment will be denied treatment for their opiate dependence no matter how well they may be doing with it.

Every woman with children will now have the additional burden of a babysitter so that they can attend the program.

Making patients have a designated driver is really against all the scientific evidence that is known about a stable patient taking methadone.

This is an issue of legislators delving into something and making assumptions about things that they know nothing about. They do not understand that opiate addiction is a brain disorder and that methadone is a medication and they do not view patients as seeking recovery.

It is interesting to note that these regulations do not include other powerful medications that can cause impairment. They are focused on methadone and patients in medicated assisted treatment because they harbor prejudices and stigma towards them.

Methadone has been evaluated for over forty years throughout the world. Studies evaluating the functional potential of methadone patients have found no differences between the patients and control groups. In fact in some studies the patients had a faster reaction time and another study that followed driving records found patients were safer drivers (Gordon, 1994).

What is the most disturbing is that Indiana legislators are making regulations without consulting any professionals, researchers or patients to first assess the needs and impact of the new regulations. One would hope that there intention would be to make Indiana a better place for all of it’s citizens.

The MAG is Working in Indiana

The MAG of Indiana NAMA’s Indiana Chapter is working to mobilize patients and advocates to speak out against this legislation. Even if you live in another state it is important that you write to these legislators and tell them how devastating this will be to patients.

What Can You Do?

You can download the following to help with contacting legislators:

Indiana Legislators Target Methadone Patients Flyer

Who to Write To

District Reps for methadone clinics

House Bill 1258

Courier-Journal Article

Patient Info Sheet for SB 0157 (Designated Driver)

Petition for Designated Driver

Phone Script for Designated Driver

Monday, November 12, 2007

Porter Starke Ready to Open New Indiana Clinic

National Alliance of Methadone Advocates
Press Release

Contact Person:
Joycelyn Woods, Executive Director
nama.president@Verizon.net
1.212.595.6262

For Release
November 12, 2007

Located in Valparaiso the clinic is attached to the main Porter-Starke Services building has everything in place except the actual methadone according to advocate and director Carmen Arlt. The clinic has been inspected by state and federal officials and is now waiting for the federal certificate. Once the certificate is received the clinic could be open within days. According to Arlt they are expecting a large number of transfer patients from the Gary area since many of the patients that attend those clinics are from the area

Carmen Arlt is also director of NAMA’s Indiana Chapter The MAG and is one of the few patient advocates to be recognized with the prestigious Marie (Dole-Nyswander) Award.

About
Since its beginning over 40 years ago methadone maintenance has been the most effective treatment for narcotic addiction. In spite of its success, methadone maintenance is often disparaged as a "substitute drug" by those who ignore the positive benefits that it has clearly brought to society. Such attitudes negatively impact on methadone treatment in a variety of ways, but it is the methadone patients themselves who are particularly stigmatized and harmed. Patients are mistreated and misinformed and considered as social outcasts. They are victims of discrimination in health care, the job market, education, insurance and housing. The National Alliance of Methadone Advocates (NAMA) was organized as a formal mechanism for methadone patients to voice their own needs and to form a strong, unified public presence on their behalf. The primary objective of NAMA is to advocate for the patient in treatment by destigmatizing and empowering methadone patients. First and foremost, it can confront the negative stereotypes that impact on the self esteem and worth of many methadone patients with a powerful affirmation of pride and unity.
Website: http://www.methadone.org


Contact Persons:
Joycelyn Woods, Executive Director, ediretor@methadone.org
Roxanne Baker, President, president@methadone.org
Phone/FAX: 212.595.nama

See attached article from Post Tribune.
###

Attachment
Final touches on clinic
November 10, 2007
By Teresa Auch Post-Tribune staff writer
VALPARAISO -- The new methadone clinic at Porter-Starke Services is ready to open, just as soon as the federal government gives approval.
The clinic, one of 13 in the state, was supposed to open July 1, Carmen Arlt, director of addiction services said. But the group wanted to put in more safety features, such as cameras and locks, to make the community and staff feel safe.
"We were slowed down by the process of renovation," Arlt said.
The clinic, which is attached to the main Porter-Starke Services building at 701 Wall St. in Valparaiso, has everything in place except the actual methadone.
A camera hovers over the entrance, as do several others in the lobby. Patients coming to get a prescription of methadone must first sign in at a front window.
They then move to another window, walled off from the lobby, to take their dosage.
The clients must sign electronically and then swallow the liquid in front of the registered nurse giving the dose, nurse staff member Don Sison said.
"Sometimes we engage in conversation after they have taken it to make sure they have swallowed it," Sison said.
The conversation also allows the nurses to get a feel for how patients are doing.
The clinic includes several side rooms for physicals, mandatory drug tests and interviews. Anyone who wants to become, and remain, a patient must prove they have tried other measures and that they are making improvements in their lives, Arlt said.
As for the dispensary, the room is made of steel walls, the door has a double lock, along with motion detectors.
Anyone entering the room has to have a nursing certificate posted on a board inside. The methadone supplies are kept in a special safe.
Arlt said the clinic has passed all levels of state and federal regulations.
"We're actually more safe over here than a bank," she said.
As soon as the federal government gives official certification, the clinic can be open within a few days.
That could happen anywhere from days to a few weeks from now, she said.
Arlt said she expects to see a heavy volume of patients soon.
The state government has warned her that about 60 percent of the patients who go to the clinics in Gary are from Porter County and will likely go to Porter-Starke once its clinic opens.

Thursday, May 17, 2007

Leaders of NAMA’s Swedish Affiliate Svenska Brukarforeningen (SBF) Report to Police for Handing Out Clean Needles

National Alliance of Methadone Advocates
Press Release


Contact Person: Joycelyn Woods, President
nama.president@Verizon.net
1.212.595.nama

For Release
May 17, 2007

On May 4 SBF’s President, Berne Stålenkrantz and the Stockhom Director, Johan Stenbäck presented themselves to the Norrmalm Police Station in Stockholm for handing out clean needles to drug users.

The purpose of the action was to get an official assessment of the their crime and to bring to the public the fact that Sweden does not allow syringes to be sold in pharmacies as is done is all other countries in the European Union (EU). SBF is also considering reporting Sweden to the European Union for its failure to comply with EU rules surrounding the common market.

In southern Sweden needle exchange programs have been keeping the spread of HCV nd HIV under control for the past 20 years. County and Town Councils have been allowed to establish needle exchange programmes if they so wish. However in Stockholm no such programs have been established.

According to Stålenkrantz if the penalty is mild they will continue with what they are doing. However after SBF publicized that they were providing drug users with clean needles the organization suddenly found its financing from Stockholm City Council under threat.

Stålenkrantz also reported that a colleague suffering from a Hepatitis C was planning to report the city's social services department to the police because he has contracted a deadly illness after being refused clean syringes. He will also state that he was a victim of SBF’s having received clean syringes from the organization.

Needle exchange programs have been used worldwide for the past twenty years and provides a way for drug users to avoid the risks of drug use as well as a way to access support services including treatment.

"We are handing out syringes for purely humanitarian reasons. And we are forced to do so since society is not providing this type of healthcare," said Stålenkrantz.

Friday, May 04, 2007

NAMA Calls for An End To Using The Term Substitution Treatment Asking That Governments and Their Agencies and Organizations End Its’ Use

National Alliance of Methadone Advocates
Press Release

Contact:
Joycelyn Woods MA-CMA (212) 595-NAMA/6262


For Release:
May 4, 2007



The National Alliance of Methadone Advocates, our international affiliates and chapters in the United States call on all governments, governmental agencies and international organizations to end the use of “Substitution Treatment” when referring to medication assisted treatment (MAT) for opiate addiction.

The term “Substitution Treatment” infers that any medication used in the treatment of opiate dependence is a substitute. No other medication is referred to in this manner creating significant misunderstandings towards the medication and especially the patients. The use of “Substitution Treatment” stigmatizes patients receiving treatment for the opiate dependence, promotes ignorance and pollutes the development and growth of this life saving medication for those needing help for their opiate dependence.

Governments have rejected buprenorphine and particularly methadone because they it is viewed as merely a substitute for heroin or other illicit drugs. Officials in rejecting these medications have expressed the belief that their citizens should have the right to an effective treatment. Thus hundreds of thousands of opiate dependent individuals “are being denied” the most effective treatment because “Substitution Treatment” is misleading and confusing.

In the United States the term Substitute and Substitution Treatment is only used to denigrate both methadone and buprenorphine treatments. Calling these medications a substitute has been used to hurt Patients by denying them opportunities and other benefits that they deserve and have worked for. Thus, in the United States only those against methadone and buprenorphine call them a Substitute.

At Bratislava in 2006 Dr. Icro Maremmani, the President of Europad called for his European colleagues to end the use of “Substitution Treatment. He asked his colleagues to follow the philosophy and principles of Drs. Dole and Nyswander who believed that opioid dependence and addiction was a medical condition and conceptualized the drug dependent person as a person with a brain metabolic disorder.

The last years of Dr. Dole’s life were spent working to resolve the stigma and prejudice that affects patients in medication assisted treatment. Dr. Dole was acutely aware of the stigma that terms like “Substitution Treatment” create towards patients. He always spoke out against any inference that medication assisted treatment was a substitute. In his experience, methadone and more recently buprenorphine were medications that stabilize the endogenous opioid system damaged by narcotics.

We, at the National Alliance of Methadone Advocates believe that the use of Substitute or Substitution Treatment denigrates this treatment. And that by denigrating this treatment patients receiving medication assisted treatment are injured.

As patients we reserve the right to define ourselves and our treatment. It is therefore the spirit of our own self identity we ask governments and their agencies, organizations and professionals to cease using “Substitution Treatment. Methadone and buprenorphine are medical treatments and should be defined as “Medication Assisted Treatment” or “Opiate Agonist Therapy”.



It is therefore in the spirit of our own self identity we ask governments and their agencies, organizations and professionals to cease using “Substitution Treatment. Methadone and buprenorphine are "medical treatments" and should be defined as such. However if you must put a name to addiction treatment then we suggest “Medication Assisted Treatment” or “Opiate Agonist Therapy”.

Thursday, April 12, 2007

Méta d'âme Announces New Housing Initiative for Methadone Patients in Montreal

National Alliance of Methadone Advocates
Press Release

Contact Persons:


Joycelyn Woods, President
nama.president@Verizon.net
1.212.595.nama

Guy Pierre Levesque, Méta d'âme
guypierrelevesque@yahoo.com

For Release:
April 12, 2007



Méta d'âme NAMA’s affiliate in Montreal has announced a new housing project that will provide housing and peer services to methadone patients. Construction of a new building will begin in August with the building of 22 units that consisting of studio and 1-bedroom apartments. The building will have a green roof and community hall for meetings. Meta d'âme will own and manage the project with peer workers in collaboration with clinic referrals. Guy Pierre Lévesque spokesperson for Méta d'âme reports that the organization will also occupy half of the ground floor starting June 2008.

The housing project is named Promethéus (Promethe) from the Greek god. A favorite of Zeus Promethe was punisheed for disobedience because he stole fire from the gods and gave it to mortals for their use. This was the beginning of enlightenment for man. An appropriate name for the project Promethean refers to events or people of great creativity, intellect and boldness.

Also in the planning is a French International Methadone Conference and other medicated assisted treatment (MAT) for opiate dependency. Translations will be made available in English. Méta d'âme will be involved in the planning and also include peer-working at the conference. In addition to the conference Méta d'âme is involved in the development of a Canadian Methadone Association.

“It is possible to make things happened if we believe in what we do,” says Lévesque. Therefore it appears that the impetus of Méta d'âme is creating some important advances in Canada.

Monday, April 09, 2007

MOUNT SINAI TO ABANDON AFRICAN-AMERICAN AND HISPANIC PATIENTS OF EAST HARLEM

National Alliance of Methadone Advocates
Press Release

Contact:
Joycelyn Woods MA-CMA (212) 595-NAMA/6262


For Release:
April 9, 2007

The Mount Sinai Hospital is planning to close the Narcotic Rehabilitation Center (NRC) a program with an international reputation for excellence in treating opiate addiction. After 37 years of providing rehabilitation services to Upper East Side residents afflicted with opiate addiction, Mount Sinai has determined that there is no longer any room for the program.

Even after accepting funds for the renovation of the facility from the New York State Office of Substance Abuse Services (OASAS) the hospital appears to be moving to quickly close NRC. In NRC’s place Mount Sinai is planning a multi-million dollar project that will include luxury high-rise apartments. It is difficult to comprehend Mount Sinai’s decision to eliminate a program that has been important to the local neighborhood. The situation could be easily averted since NRC can be easily relocated to the selected site that is renovated, licensed and ready to open. Therefore it is difficult to understand why Mt. Sinai can not find a way to keep these valuable services.

Has Mount Sinai Forgotten it’s Mission?

The National Alliance of Methadone Advocates (NAMA) has already begun to hear from fearful patients and their concerns about having to go to another program that they do not know. Certainly, patients will have to travel into other neighborhoods for treatment, change their schedules and develop new relationships with program staff. This creates stress for patients and their families. And now with fewer options to treatment in East Harlem any increases in drug use could easily develop into a public health crisis.

NRC that serves 700 patients has a international reputation for providing quality medicated assisted treatment and is known for having exceptional services. The programs that will have to take on the responsibility of accepting these patients do not have the services that NRC has developed over the years. Programs in Northern Manhattan are already operating close to capacity and certainly do not have room for large numbers of patients creating a carry over effect. If the 7 closest programs accepted 100 patients each the burden on them would be tremendous. Program staff already over worked and stressed will not be able to provide the level of care that they were providing. Therefore a large number of patients from an area with pockets of destitution will not be able to obtain the services that they need to change their lives. In addition to the 700 patients from NRC at least another 3500 patients will be affected by the closing of NRC.

The Harlem area and nearby neighborhoods will be impacted from the effects of the closing of NRC. The improvements that the Harlem area has experienced in the last decade will begin to deteriorate. Individuals seeking help for their opiate dependence will be turned away from local programs, a rarity in New York City. Crime in East Harlem will undoubtedly increase and spill into neighboring communities. The standard of living will be reduced for all as hospitals admissions increase and other public health indicators increase (i.e. HIV, overdose deaths, TB). Therefore the impact of NRC closing on the community and on the city is not insignificant.

NAMA urges Mount Sinai to re-think their decision and to continue with the decision to utilize the site that has been selected and is ready for the program to move into. Proceeding with the current decision to close NRC is an indication that the needs of community are not important in comparison to the new luxury high rise residents. NAMA believes that the patients of NRC and the East Harlem community deserve more from Mount Sinai and will make every effort to insure that the patients of NRC and the community are not forgotten. East Harlem is a vibrant community and the people deserve the right to have access to medicated assisted treatment within their community.

Saturday, March 10, 2007

STOP METHADONE IGNORANCE

National Alliance of Methadone Advocates
Press Release
Contact Person: Joycelyn Woods, President


For Release:
March 10, 2007




It is not uncommon for individuals with a long history of illicit opiate use to remain in methadone treatment as a long term patient. Many often say that without methadone treatment they would probably be dead. Other forms of treatment were not effective and they had come to believe that they would die an "addict". Numerous studies have demonstrated that the majority of persons who leave methadone treatment revert to illicit heroin or other opioid use in relatively short time though of course there are exceptions.



NIDA and NIH considers "addiction" as a chronic relapsing brain disorder. A full text article, The Neurobiology of Addictive Behaviors and its Relationship to Methadone Maintenance by Stimmel and Kreek is available from, http://www.mssm.edu/msjournal/67/page375_380.pdf



You get an excellent idea of the benefits of methadone maintenance by visiting a petition web site that was recently established by NAMA to counter anti-methadone groups trying to restrict this valuable therapy. Read the patient reports on the petition and you will get a significant understanding of the benefits to the patients of this form of therapy.



However recently there have been an increase in methadone overdose deaths attributed to an increase in prescribing methadone for pain medication. Also methadone has been in the media recently adding to the fervor and sensationalism.



The change in regulations created a more realistic situation for both programs and patients seeking recovery. However recently several sensational websites are promoting stricter regulations on methadone treatment in an effort to end the increase overdose deaths. These measures will be ineffective as most of the deaths are due to a number of factors including mishandling of medication. In an effort to protect our life saving treatment and to make methadone safer for pain management NAMA recommends education rather than restrictions.



We are also asking patients and their families to sign a petition "Methadone Patients Against Hysteria and Further Restrictions". The petition in brief, reads as follows:



We are Methadone Patients, Providers, Families and Friends AGAINST the Hysteria which is calling for Further Restrictions on the Prescribing of Methadone."
http://www.thepetitionsite.com/takeaction/360731625